Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.
Dr. Augusto Villanueva Rodriguez
Advertisement
Dr. Augusto Villanueva Rodriguez is medical director of the Liver Cancer Program at NYU Langone Health.
Articles by Dr. Augusto Villanueva Rodriguez
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer
2
FDA Approves Hyrnuo in Some with Locally Advanced/Metastatic NSCLC
3
FDA Accepts NDA for Zidesamtinib in Previously Treated ROS1+ NSCLC
4
FDA Grants Fast Track Status to New Gastric Cancer Treatment
5
